Many residents in New England are going to have more choices in the public exchanges this fall, as some insurers' growth strategies are tested.
Many residents in New England are going to have more choices in the public exchanges this fall, as some insurers' growth strategies are tested.
After New Hampshire’s first open enrollment period — where WellPoint’s Anthem Blue Cross was the only carrier and one with a narrow network that dismayed some consumer and hospital advocates — four insurers have announced plans to sell on and off the Granite State’s exchange.
The New Hampshire Insurance Department has just licensed Maine Community Health Options, the second federally-supported cooperative plan to enter the state, following the Massachusetts-based co-op Minuteman Health. Along with them, Harvard Pilgrim and Assurant Health will be selling plans for the first time in the exchange, leaving some New Hampshire residents with five choices of carriers, when just last year they only had one.
Read the full story here: http://bit.ly/1iUZl9X
Source: Healthcare Payer News
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More